FIELD: medicine.
SUBSTANCE: invention relates to a method of treating hepatitis B virus infection in a subject in need thereof, comprising administering to a subject a capsid assembly and peginterferon alfa-2a inhibitor, wherein said capsid assembly inhibitor is compound (1) or a pharmaceutically acceptable salt thereof. Invention also relates to a composition for treating hepatitis B virus infection, as described above.
1.
EFFECT: use of the disclosed combination enables more effective suppression of hepatitis B virus replication.
12 cl, 2 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHOSPHORUS(N)AMIDATEACETAL AND PHOSPH(OH)ATACETAL COMPOUNDS | 2019 |
|
RU2796403C2 |
| DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | 2015 |
|
RU2742305C2 |
| HEPATITIS C VIRUS INHIBITORS | 2010 |
|
RU2544010C2 |
| BENZO[b]THIOPHENE STING AGONISTS FOR TREATMENT OF CANCER | 2018 |
|
RU2771811C2 |
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2011 |
|
RU2599248C2 |
| HEPATITIS B (HBV) INHIBITOR | 2017 |
|
RU2666727C1 |
| QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | 2008 |
|
RU2493160C2 |
| SERINE PROTEASE INHIBITORS | 2006 |
|
RU2441020C2 |
| METHODS FOR INCREASING STABILISATION OF HYPOXYA INDUCED FACTOR-1 ALPHA | 2010 |
|
RU2521251C2 |
| COMBINED THERAPY WITH TETRACYCLIC QUINOLONE ANALOGUES FOR CANCER TREATMENT | 2016 |
|
RU2752506C2 |
